Archive for the ‘Gene Therapy Research’ Category

LONDON Scientists have used genome sequencing technology to control an outbreak of the superbug MRSA in a study that could point to faster and more efficient treatment of a range of diseases.

The work adds to a burgeoning body of research into better techniques for diagnosing disease more quickly and at an earlier stage to allow more effective treatment and reduce health care costs.

Much of this is being driven by whole genome sequencing, which has enabled scientists to identify the genetic markers for a range of afflictions.

MRSA, or Methicillin-Resistant Staphylococcus Aureus, is a drug-resistant bacterial infection, or superbug, and major public health problem. When outbreaks occur in hospitals it can lead to the closure of whole wards and lengthy investigations.

The bug kills an estimated 19,000 people in the United States alone each year, and even when the infection is successfully treated it can double the average length of a hospital stay and thereby increase health care costs.

A team of scientists from the Wellcome Trust Sanger Institute, the University of Cambridge and genome sequencing company Illumina Inc, used samples from a 2009 MRSA outbreak in a hospital neo-natal intensive care ward to recreate and respond to it, as if in real time.

They found that genome sequencing produced results in roughly 24 hours, using the latest technology from Illumina, gave much more detailed information.

The researchers were able to identify the particular strain of MRSA causing the outbreak, and which strains were not, quickly enough to feed back into treatment and nip the outbreak in the bud faster than current clinical testing methods.

"I think we are at the very beginning of an explosion of evidence to support the use of whole genome sequencing in public health," Sharon Peacock of Cambridge University, who led the study, told Reuters.

The research, published in the New England Journal of Medicine, comes hot on the heels of similar work done on MRSA and Clostridium difficile by a team from Oxford University with Illumina and a group of hospitals in Britain.

See original here:
Real-time gene sequencing used to fight MRSA

Public release date: 17-Jun-2012 [ | E-mail | Share ]

Contact: Quinn Eastman qeastma@emory.edu 404-727-7829 Emory University

Scientists have found a master regulator gene needed for the development of M cells, a mysterious type of intestinal cell involved in initiating immune responses.

M cells act like "conveyor belts," ingesting bacteria and transporting substances from the gut into Peyer's patches, specialized tissues resembling lymph nodes in the intestines. Better knowledge of M cells' properties could aid research on oral vaccines and inflammatory bowel diseases.

A team of researchers at Emory University School of Medicine and RIKEN Research Center for Allergy and Immunology in Japan has identified the gene Spi-B as responsible for the differentiation of M cells.

The results are published Sunday, June 17 in the journal Nature Immunology.

"This discovery could really unlock a lot of information about the sequence of events needed for M cells to develop and what makes them distinctive," says co-author Ifor Williams, MD, PhD, associate professor of pathology and laboratory medicine at Emory University School of Medicine. "M cells have been difficult to study because they are relatively rare, they are only found within the Peyer's patches and can't be grown in isolation."

Scientists at RIKEN, led by senior author Hiroshi Ohno, MD, PhD, teamed up with Williams' laboratory, taking advantage of a discovery by Williams that a protein called RANKL, which is produced by cells in Peyer's patches, can induce M cell differentiation. Research scientist Takashi Kanaya is first author of the paper.

Kanaya and colleagues found that the gene Spi-B is turned on strongly at early stages of M cell differentiation induced by RANKL. Their suspicion of Spi-B's critical role was confirmed when they discovered that mice lacking Spi-B do not have functional M cells, and the cells in the intestines lack several other markers usually found on M cells.

"It was somewhat surprising to find Spi-B expressed in intestinal epithelial cells," Williams says. "Because Spi-B is known to be important for the development of some types of immune cells, it was thought to be expressed only in bone marrow-derived cells."

More:
Control gene for 'conveyor belt' cells could help improve oral vaccines, treat intestinal disease

Public release date: 18-Jun-2012 [ | E-mail | Share ]

Contact: Professor Hannes Lohi hannes.lohi@helsinki.fi 358-919-25085 University of Helsinki

Researchers at the University of Helsinki and the Folkhlsan Research Center, Finland, have identified the genetic cause of early-onset progressive cerebellar degeneration the Finnish Hound dog breed. The study, led by Professor Hannes Lohi, revealed a new disease mechanism in cerebellar degeneration. A mutation was identified in the SEL1L gene, which has no previous link to inherited cerebellar ataxias.

This gene find is the first in canine early-onset cerebellar degeneration, and has enabled the development of a genetic test to help eradicate the disease from the breed. At the same time, SEL1L represents a novel candidate gene in human early-onset degenerative ataxias.

The research was published in the scientific journal PLoS Genetics on June 14, 2012.

Inherited ataxias affect both humans and animals. In humans, the hereditary ataxias are a heterogeneous disease group, characterized by cerebellar degeneration and dysfunction. The cerebellum is a part of the brain that is involved in coordination of movement. Degeneration of the cerebellar structures causes ataxia, which is a neurological sign of defective motor coordination that can affect gait, balance, speech and gaze. Approximately 20 known disease-causing genes have been identified in both autosomal recessive and dominant ataxias in humans but the genetic background of canine cerebellar ataxias has remained largely unknown.

The clinical signs of Finnish Hound cerebellar ataxia are present by the age of two months. The affected puppies have difficulty in controlling their leg movements and keeping their balance. The disease progresses rapidly, and in the end eating becomes impossible because of uncontrolled head movements. There is no cure for the disease and affected puppies have to be euthanized.

The research conducted by Professor Lohi and co-workers revealed marked neuronal loss in the cerebellar cortex of affected Finnish Hound puppies. By comparing the genomes of affected and healthy dogs, the cause of the disease was pinpointed to a single nucleotide change in the SEL1L gene. The nucleotide alteration causes an amino acid change in the encoded SEL1L protein.

"The identified ataxia gene is the first early-onset degenerative cerebellar ataxia gene that has been identified in dogs", says professor Hannes Lohi. In addition to Finnish Hounds, cerebellar degeneration has been identified in several other dog breeds.

"The SEL1L gene has not been previously connected to cerebellar ataxias in any species and it represents a novel candidate gene for human early-onset ataxias", Lohi continues. "In fact, we have already screened a small cohort of human patients for possible disease-causing SEL1L mutations".

See the original post here:
New cerebellar ataxia gene identified in dogs

Why Genetically Engineered Food Is Dangerous

New report by genetic engineers Press release for immediate release Earth Open Source 17 June 2012

LONDON, UK - Aren't critics of genetically engineered food anti-science? Isn't the debate over GMOs (genetically modified organisms) a spat between emotional but ignorant activists on one hand and rational GM-supporting scientists on the other?

A new report released today, "GMO Myths and Truths",[1] challenges these claims. The report presents a large body of peer-reviewed scientific and other authoritative evidence of the hazards to health and the environment posed by genetically engineered crops and organisms (GMOs).

Unusually, the initiative for the report came not from campaigners but from two genetic engineers who believe there are good scientific reasons to be wary of GM foods and crops.

One of the report's authors, Dr Michael Antoniou of King's College London School of Medicine in the UK, uses genetic engineering for medical applications but warns against its use in developing crops for human food and animal feed.

Dr Antoniou said: "GM crops are promoted on the basis of ambitious claims - that they are safe to eat, environmentally beneficial, increase yields, reduce reliance on pesticides, and can help solve world hunger.

"I felt what was needed was a collation of the evidence that addresses the technology from a scientific point of view.

"Research studies show that genetically modified crops have harmful effects on laboratory animals in feeding trials and on the environment during cultivation. They have increased the use of pesticides and have failed to increase yields. Our report concludes that there are safer and more effective alternatives to meeting the world's food needs."

Another author of the report, Dr John Fagan, is a former genetic engineer who in 1994 returned to the National Institutes of Health $614,000 in grant money owing to concerns about the safety and ethics of the technology. He subsequently founded a GMO testing company.

Read more:
Why Genetically Engineered Food Is Dangerous

CARLSBAD, Calif., June 18, 2012 /PRNewswire/ -- Life Technologies Corporation (LIFE) today announced the launch of three next generation GeneArt genetic engineering kits that allow molecular and synthetic biologists unprecedented speed, flexibility, precision, and efficiency for the seamless cloning, assembly, and editing of genetic material.

The GeneArt Seamless PLUS Cloning and Assembly Kit allows investigators to complete complex assembly projects in days that would take weeks with typically available methods. The kits use a proprietary enzyme mix to recognize and precisely assemble DNA fragments without the need for restriction digestion, ligation, or introduction of extra DNA sequence (seamless). The kits are designed to work with any vector a researcher chooses plus 1 to 4 fragments (or more depending on fragment sizes and workflow) in an in vitro, typically <30 minute room temperature reaction to create constructs up to 40kb in size.

The newly introduced GeneArt Seamless Cloning and Assembly Enzyme Mix is the economical choice for creating constructs up to 13kb with the option for high-throughput assembly.

The GeneArt Site-Directed Mutagenesis PLUS System can be employed to introduce deletions, insertions and substitutions ranging from small to large fragment sizes and can facilitate single or multi-site mutagenesis. Up to three sites can be edited in a single plasmid at greater than 90% efficiency. Up to 25 nucleotides can be altered in a single site, and results are delivered typically in less than three hours for plasmids up to 14 kb in size.

"Typically, mutagenesis efficiency decreases as multiple sites are targeted," said Nathan Wood, general manager and vice president of synthetic biology at Life Technologies. "The GeneArt kits maintain high efficiency over multiple sites, an advantage for our customers."

"Our scientists assemble and manipulate genetic material on a daily basis," said Wood. "They are deeply connected to the need for speed and reliability in cloning, assembly and mutagenesis systems, and they also understand that our customers need systems designed to handle different levels of complexity."

The new kits extend Life's current market-leading product offerings in assembly and mutagenesis kits, the GeneArt Seamless Cloning and Assembly Kit (for up to four fragments and constructs up to13kb), the GeneArt High-Order Genetic Assembly Kit (a yeast-based system for up to 10 fragments and constructs up to 110kb), and the GeneArt Site-Directed Mutagenesis System. With the new all-in-one enzyme/buffer mix and increased room temperature stability, the new kits offer increased flexibility, speed, and the option for high-throughput workflows. The new Mutagenesis PLUS system offers all of the single-site functionality of the current mutagenesis kits but with multi-site mutagenesis, the all-in-one enzyme/buffer mix, and increased room-temperature stability.

All products include access to Life Technologies' free online GeneArt Primer and Construct Design Tool for Seamless or High-Order Assembly and Mutagenesis: http://bioinfo.invitrogen.com/oligoDesigner/.

This tool facilitates the in silico design, assembly, or mutagenesis of a DNA molecule using GeneArt technology. The GeneArt Design Tool:

Originally posted here:
Life Technologies Launches Expanded, Next Generation GeneArt® Kits for Mutagenesis, Cloning and Assembly

Scientists at the University of California at Irvine and and the Pasteur Institute in Paris say theyve used genetic engineering to create mosquitoes that cant infect people with malaria. They used Anopheles stephensi mosquito a major source of malaria in India and the Middle East but say the technique could be used on dozens of different types of mosquitoes. Malaria parasites picked up by these mosquitoes are killed by the the mosquitoes immune systems. So the insects cant transmit malaria through their bites. The scientists made their announcement on June 17, 2012, and their paper was published in the Proceedings for the National Academy of Sciences.

Scientists have genetically altered the Anopheles stephensi mosquito so that their immunes systems kill the malaria parasite. They say their technique could be used with dozens of different types of mosquitoes.

More than 40 percent of the worlds population lives in areas where there is a risk of contracting malaria. The World Health Organization says there were about 216 million cases of malaria and an estimated 655,000 deaths in 2010. The deaths are largely infants, young children and pregnant women. Most deaths occur among children living in Africa where a child dies every minute from malaria.

Anthony James of UC Irvine said:

Our group has made significant advances with the creation of transgenic mosquitoes But this is the first model of a malaria vector with a genetic modification that can potentially exist in wild populations and be transferred through generations without affecting their fitness.

I did not talk to these scientists, and I have questions. What happens to the mosquitoes already in the wild, which carry the malaria parasite? Do they breed with the genetically modified mosquitoes so that some inherit malaria-killing immune systems? There will be another question for some. Is it wise to release genetically modified mosquitoes into the wild? For the families of children who might die of malaria, the answer is clear: pursue this promising line of research. The rest of us will need to acknowledge that we live in a world where the questions themselves are getting tougher.

Bottom line: Scientists at the University of California at Irvine and and the Pasteur Institute in Paris have used genetic engineering to create mosquitoes whose immune systems kill the malaria parasite. These mosquitoes, then, cant transmit malaria.

Read this article:
Genetically-engineered mosquitoes can’t transmit malaria

Newswise BETHESDA, MD June 18, 2012 -- In cancer, the genome is shot to hell," Columbia University cell biologist I. Bernard Weinstein, M.D., famously said in 1989. Since then, researchers have catalogued the mutations that drive many human cancers. But since cancer takes years to develop, experiments on shorter-lived species have been critical in developing new diagnostics and therapeutics. Scientists who work on human cancer and those who use other species as stand-ins for humans will get together June 17-20, 2012 at the Genetics Society of Americas (GSAs) Model Organism to Human Biology (MOHB): Cancer Genetics Meeting at the Omni Shoreham Hotel in Washington, D.C.

Unlike a single-gene disease inherited through either sperm or egg, the genetic changes of cancer strike somatic (from the Greek soma meaning body) cells including those cells that make up internal organs. In affected organs, these somatic cells may have an underlying susceptibility mutation present. Once a cancer begins, an oncogene, a gene that has the potential of causing cancer, is turned on or a tumor suppressor turned off and other changes ensue. The changing nature of cancer explains why treating the disease requires staying steps ahead.

Animal models have been instrumental for working out the pathways through which all human solid tumors form. Current knowledge of cancer genes is a tribute to the basic research that has been performed over the past four decades, the majority of it in model systems, Bert Vogelstein, M.D., director, Ludwig Center at Johns Hopkins University and Investigator, Howard Hughes Medical Institute said. Dr. Vogelstein, a keynote speaker at the MOHB: Cancer Genetics Meeting has identified the sequence of genetic changes behind colorectal cancer.

Looking at the big picture, Eric Green, M.D., Ph.D., director of the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) and another speaker at the MOHB: Cancer Genetics meeting said, Cancer is a disease of the genome. The more knowledge we gain about the structure and function of genomes, the more we will be able to learn about the genomic changes responsible for different types of cancer.

The cancer-genome connection is why NHGRI began partnering with the National Cancer Institute in 2005 to create The Cancer Genome Atlas, which will describe the genomes of 20 cancer types.

Quite a varied group of organisms have taught us about human cancers, explained Phil Hieter, Ph.D., (University of British Columbia), President of the GSA, Each model organism has its own advantages and disadvantages for the study of a particular process. The aggregate is much more powerful, so it makes great sense to shuttle among species in studying the mechanisms and mutations associated with cancer. Thats what this conference is all about.

Thanks to evolution, the cancers of model organisms reflect derangement in many of the same genes and pathways that fuel human cancers. The model organism Encyclopedia of DNA Elements (modENCODE) project, begun in 2009, is identifying the genetic controls of two popular model organisms: the roundworm Caenhorhabditis elegans and the fruit fly Drosophila melanogaster. ModENCODE has greatly advanced our knowledge of genome function in model systems, which is foundational knowledge for deciphering the biological consequences of cancer-associated genomic changes, said Dr. Green, who will discuss it at the meeting.

The mini-modENCODE Symposium being held at GSAs MOHB: Cancer Genetics Meeting will be followed by a symposium on June 20-21 hosted by NHGRI at the NIH campus to celebrate the projects accomplishments as it draws to completion this year. For more information about the NHGRI symposium, please see http://www.genome.gov/27548680.

ABOUT THE MODEL ORGANISM TO HUMAN BIOLOGY MEETING: The GSA MOHB Meeting has been held every other year since 2006. The GSA Board of Directors developed this meeting to enable basic research scientists studying genetic diseases in model organisms and scientists studying these diseases in humans to have a forum for discussion of their findings and to forge collaborative investigations.

ABOUT GSA: Founded in 1931, the Genetics Society of America (GSA) is the professional membership organization for scientific researchers, educators, bioengineers, bioinformaticians and others interested in the field of genetics. Its nearly 5,000 members work to advance knowledge in the basic mechanisms of inheritance, from the molecular to the population level. GSA is dedicated to promoting research in genetics and to facilitating communication among geneticists worldwide through its conferences, including the biennial conference on Model Organisms to Human Biology, an interdisciplinary meeting on current and cutting edge topics in genetics research, as well as annual and biennial meetings that focus on the genetics of particular organisms, including C. elegans, Drosophila, fungi, mice, yeast, and zebrafish. GSA publishes GENETICS, a leading journal in the field and an online, open-access journal, G3: Genes|Genomes|Genetics. For more information about GSA, please visit http://www.genetics-gsa.org. Also follow GSA on Facebook at facebook.com/GeneticsGSA and on Twitter @GeneticsGSA.

Here is the original post:
Genetics Meeting Surveys the Cancer Genome Landscape

Public release date: 18-Jun-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 18, 2012A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

"This is a very novel approach for addressing the huge medical problem of cocaine addiction," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

In the article "AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior," (http://online.liebertpub.com/doi/pdfplus/10.1089/hum.2011.178) a team of researchers from Weill Cornell Medical College (New York, NY), The Scripps Research Institute (La Jolla, CA), and Cornell University (Ithaca, NY) used a virus-based delivery vehicle in mice to transfer a gene that produces a protein capable of binding to cocaine present in the blood, preventing the cocaine from crossing into the brain. The protein is a monoclonal antibody that sequesters cocaine, making the vaccinated mice resistant to the drug's effects. Whereas unvaccinated mice exhibited hyperactivity when exposed to intravenous cocaine, the immunized mice showed no effects, according to authors Jonathan Rosenberg, et al.

###

About the Journal

Human Gene Therapy (http://www.liebertpub.com/hum), the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of contents and a free sample issue may be viewed online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

About the Publisher

Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website (http://www.liebertpub.com).

Original post:
Anti-cocaine vaccine described in Human Gene Therapy Journal

AMSTERDAM, The Netherlands, June 18, 2012 /PRNewswire/ --

uniQure, a leader in the field of human gene therapy, announced today the extension of its collaboration with Protein Sciences Corporation ("Protein Sciences") for the exclusive use of Protein Sciences' expresSF+ (SF+) insect cell line in uniQure's AAV gene therapy programs for three specific disease indications. uniQure has the option to extend this exclusivity further into additional indications in the future.

"This agreement strengthens uniQure's gene therapy platform and further demonstrates the quality of the cell line developed by Protein Sciences." said Joern Aldag, Chief Executive of uniQure. "Protein Sciences' cell line license agreement with Merck made earlier this year and the anticipated approval of its influenza vaccine FluBlok implies SF+ technology will hold a prominent place in the manufacture of biologics."

The SF+ cell line developed by Protein Sciences is an integral component of uniQure's validated, world leading manufacturing platform. uniQure believes that this platform is the only commercially-scalable platform available for manufacturing AAV gene therapy products.

Financial terms were not disclosed.

About uniQure

uniQure is a world leader in the development ofhuman gene based therapies.uniQure has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform.This proprietary platform can be applied to a large number of rare(orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of focusing on this sector of the industry. Further information can be found at http://www.uniqure.com.

More:
uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy

ROYAL OAK, Mich., June 17, 2012 (GLOBE NEWSWIRE) -- Woodside Animal Hospital announced they have added both stem cell therapy and cold laser therapy to their suite of services. These two cutting edge treatments are done entirely in-house, no third-party lab work is required. Royal Oak veterinarian Dr. John Simon is the first Michigan veterinarian to provide pets with in-house adult stem cell therapy. The stem cells are derived from the pet's fat deposits and absolutely no embryonic tissue is used.

"As a holistic veterinarian, I am committed to providing high quality, cutting-edge care that combines traditional veterinary care with advanced holistic treatments," said Dr. Simon. "Our in-house stem cell therapy and cold laser therapy procedures alleviate pain in limping dogs and promote internal healing following an injury. I also recommend these procedures for pets with osteoarthritis."

Cold laser therapy is a non-surgical approach to pain management. Holistic equine veterinarians have used the procedure for over 20 years to treat injuries and joint pain. Today, veterinarians are using cold laser therapy to provide natural pain relief for injured pets.

According to Dr. Simon, cold laser therapy works by using a low-level energy beam to penetrate just below the skin's surface. Injured cells use the laser's energy to repair cellular damage. This provides relief for pain and swelling following a soft tissue injury, such as a ligament, tendon or muscle strain.

"Cold laser therapy is a revolutionary treatment for natural pain management in animals," said the Royal Oak veterinarian. "Laser therapy allows for advanced pain management, especially for pets suffering from chronic conditions or soft tissue injuries."

Woodside Animal Hospital also provides in-house pet stem cell therapy. This treatment uses adult stem cells collected from a dog's fat deposits to promote the growth of new soft tissue and cartilage. By performing the whole procedure in the clinic, the stem cells can be harvested and re-injected on the same day.

"Our in-house pet stem cell therapy is an affordable, same-day treatment that helps dogs suffering from joint pain, osteoarthritis, soft tissue injuries and hip dysplasia," said Dr. Simon. "As pets age, it's natural that their range of movement becomes restricted. While oral joint care supplements and prescription painkillers can help, medication alone cannot restore a full range of movement. Our treatments help restore activity and movement."

In addition to cold laser therapy and stem cell therapy, Dr. Simon also provides holistic treatments for cancer in dogs, cat and dog rashes, and dietary needs. The Royal Oak practice is a full-service animal hospital with wellness care, vaccinations and surgical procedures.

Dr. Simon is active in the greater Detroit veterinary community, serving as the past president of the Oakland County Veterinary Medical Association and as a board member for the Southeastern Michigan Veterinary Medical Association (SEMVMA).

Follow this link:
Royal Oak Veterinarian Dr. Simon First in Michigan to Offer In-House Adult Pet Stem Cell Therapy

Published: Sunday, June 17, 2012 at 4:01 a.m. Last Modified: Sunday, June 17, 2012 at 8:29 a.m.

The issue has farmers, grocers, scientists and foodies taking up sides, including some in Sonoma County whose livelihoods depend on agriculture setting up a fall election campaign that promises to be expensive, emotional and full of hyperbole about food safety.

Proponents of labeling, including organic farmers and food producers, say it is simply consumers' right to know what is in their food. They say labels aren't a negative, only educational, and that they may encourage shoppers to seek out more information about their eating habits.

Opponents, including traditional farmers, biotech firms and some scientists, say labeling wrongly implies that genetically engineered food is unsafe. They say labeling is misleading, expensive and will encourage costly, frivolous lawsuits.

If the initiative passes, California would be the first state to require labeling of such a wide range of foods containing genetically modified organisms, or GMOs.

"Hallelujah!" Jil Hales, owner of Healdsburg's Barndiva restaurant, said of the initiative, which qualified for the ballot last week. "I wholeheartedly support labeling, with every fiber of my being as a person and businessperson."

The state Farm Bureau has come out against the measure, but the Sonoma County Farm Bureau is taking a wait-and-see approach.

"This measure is deceptive and poorly written," said Jamie Johansson, an Oroville farmer and a vice president of the California Farm Bureau.

The proposal would require by 2014 that most processed foods disclose to shoppers that they contain ingredients derived from plants whose DNA was altered with genes from other plants, animals, viruses or bacteria.

It would require raw agricultural commodities produced entirely or in part through genetic engineering be labeled with the words "Genetically Engineered" on the front package or label. Processed foods produced in part through genetic engineering would be labeled "Partially Produced with Genetic Engineering" or "May be Partially Produced with Genetic Engineering."

See more here:
GMO showdown

15-06-2012 09:50 The multi-gene search functionality allows users to compare the expression of multiple genes at once in order to understand the relationships between these genes across cancer types and subtypes.

Read the original here:
Oncomine - Multi-Gene Search - Video

Alexandra Stern is a University of Michigan historian of medicine and expert on eugenics who lectured at the University of Houston this spring on disability rights. The author of the forthcoming "Telling Genes: The Story of Genetic Counseling in America," she spoke with Chronicle medical reporter Todd Ackerman after the lecture about the limitations of genetic medicine, whether to take advantage of for-profit company genetic tests and how eugenics didn't die out with the Holocaust.

Q: In the history of medicine, how is the early 21st century likely to be remembered? Is this the genetic era, or is that still to come?

A: The genetic era has begun, but the big question is what we do with the information we now have to help people - to what extent will it lead to cures and more effective therapies? History shows the expectations and promise of a new era's technology are often much greater than what ends up being delivered.

Q: So you think we're likely to be disappointed?

A: Unfortunately, yes. We're a society in which people are interested in their DNA, how genetics affects them, but also want quick solutions, primed by the great progress we've seen in medicine from, for instance, vaccines and antibiotics. But those magic bullets don't translate well to genetic medicine. I don't want to come across as suggesting there won't be great outcomes, but the idea that we'll simply be able to decode the genome, tailor medicines to a particular person based on their genome and cure chronic disease I think there will be a lot of unmet expectations along those lines.

Q: How much are people receiving genetic diagnoses at this point?

A: Genetic tests or diagnoses are being offered in more and more areas of clinical medicine - from neurology to cardiology to oncology. But you're probably talking about those for-profit companies doing genomic testing that return a whole scorecard of probabilities of developing certain conditions.

I think people are increasingly seeking those out and that the problem is that what they get back is unfiltered. People not only need help deciphering their information, they also need help, from a genetic counselor, dealing with the psychological decision-making quandaries they face as a result of genetic testing, how to cope if you have a higher-than-average probability of developing, say, Alzheimer's.

Q: Has enough attention been paid to ethical questions raised by the coming genetic era?

A: It depends on whom you're talking about. Discussions tend to be very fragmented: bioethicists amongst themselves; scientists amongst themselves; disability rights people amongst themselves. But as a society are we having broad-based discussions about the ethical implications, what the priorities should be and what the changes mean for people with disabilities? I don't think so.

See original here:
Sunday conversation: Historian says shadow of eugenics 'looms large'

Alexandra Stern is a University of Michigan historian of medicine and expert on eugenics who lectured at the University of Houston this spring on disability rights. The author of the forthcoming "Telling Genes: The Story of Genetic Counseling in America," she spoke with Chronicle medical reporter Todd Ackerman after the lecture about the limitations of genetic medicine, whether to take advantage of for-profit company genetic tests and how eugenics didn't die out with the Holocaust.

Q: In the history of medicine, how is the early 21st century likely to be remembered? Is this the genetic era, or is that still to come?

A: The genetic era has begun, but the big question is what we do with the information we now have to help people - to what extent will it lead to cures and more effective therapies? History shows the expectations and promise of a new era's technology are often much greater than what ends up being delivered.

Q: So you think we're likely to be disappointed?

A: Unfortunately, yes. We're a society in which people are interested in their DNA, how genetics affects them, but also want quick solutions, primed by the great progress we've seen in medicine from, for instance, vaccines and antibiotics. But those magic bullets don't translate well to genetic medicine. I don't want to come across as suggesting there won't be great outcomes, but the idea that we'll simply be able to decode the genome, tailor medicines to a particular person based on their genome and cure chronic disease I think there will be a lot of unmet expectations along those lines.

Q: How much are people receiving genetic diagnoses at this point?

A: Genetic tests or diagnoses are being offered in more and more areas of clinical medicine - from neurology to cardiology to oncology. But you're probably talking about those for-profit companies doing genomic testing that return a whole scorecard of probabilities of developing certain conditions.

I think people are increasingly seeking those out and that the problem is that what they get back is unfiltered. People not only need help deciphering their information, they also need help, from a genetic counselor, dealing with the psychological decision-making quandaries they face as a result of genetic testing, how to cope if you have a higher-than-average probability of developing, say, Alzheimer's.

Q: Has enough attention been paid to ethical questions raised by the coming genetic era?

A: It depends on whom you're talking about. Discussions tend to be very fragmented: bioethicists amongst themselves; scientists amongst themselves; disability rights people amongst themselves. But as a society are we having broad-based discussions about the ethical implications, what the priorities should be and what the changes mean for people with disabilities? I don't think so.

Here is the original post:
Eugenics shadow still 'looms large,' historian says

CHICAGO - The latest advance in prenatal genetic testing purports to offer parents more detailed information than ever about the child they are expecting. But for some, the new answers could lead to another round of questions.

The technology allows doctors to detect small or subtle chromosomal changes in a fetus - such as missing or extra pieces of DNA - that could be missed by standard tests.

Most parents will get results confirming a normal pregnancy. But some will learn that their baby has a birth defect, a developmental problem or other medical condition, and in a small number of cases the test will detect things that no one knows quite how to interpret.

The information can allow parents to prepare for early intervention and treatment, but it also could raise questions about terminating the pregnancy or lead to nagging worry over uncertain results.

The Reproductive Genetics Institute in Chicago, which has helped pioneer the rapidly developing field of prenatal diagnosis and testing, recently began offering the procedure - array comparative genomic hybridization, or array CGH for short - to any pregnant woman who wants it.

"The technology has been available for a number of years . but it has almost never been used prenatally," said Dr. Norman Ginsberg, an obstetrician specializing in prenatal genetic testing at the institute. "We think this is the beginning of the next generation of how we'll look at things."

Other medical experts see the technology as promising but have concerns about using it as a first-line test because of the potential drawbacks and the lack of published research. The availability of array CGH also raises fundamental, sometimes delicate, questions for parents.

How much do they want to know about their child's genetic makeup before he is born? How will they deal with the uncertainty of some test results, such as detection of chromosomal changes that have not been associated with diseases? Should the technology be used to identify diseases in their children that would not emerge until adulthood?

"This technology is giving genetic counselors and physicians a challenge in that there is more to discuss with patients, and it gives patients a lot more to think about in terms of what kinds of information they want to know about their baby prior to delivery," said Jennifer Hoskovec, director of prenatal genetic counseling services at the University of Texas Medical School at Houston.

Array CGH is just one of the newer microarray technologies expected to become widely available to parents.

See the article here:
Prenatal genetic test offers more information, raises questions

PADOVA, Italy, June 16 (UPI) -- Researchers in Italy suggest sexually antagonistic genetic factors in mothers may promote homosexuality in men and fertility in female relatives.

However, it is not clear whether and how the genetic factors are expressed to simultaneously induce homosexuality in men and increased fertility in their mothers and maternal aunts, the researchers said.

Andrea Camperio Ciani of the University of Padova in Italy discovered mothers and maternal aunts of gay men tend to have significantly more offspring than those of straight men.

The study, scheduled to be published in the Journal of Sexual Medicine, said it appeared at least one gene on the X chromosome resulted in more men being gay and women having more children.

"Using questionnaires, we investigated fecundity -- fertility -- in 161 female European subjects and scrutinized possible influences, including physiological, behavioral and personality factors," Ciani said in a statement. "We compared 61 females who were either mothers or maternal aunts of homosexual men. One hundred females who were mothers or aunts of heterosexual men were used as controls."

The analysis showed both mothers and maternal aunts of homosexual men show increased fecundity compared with corresponding maternal female relatives of heterosexual men.

A two-step statistical analysis found mothers and maternal aunts of homosexual men had fewer gynecological disorders; fewer complicated pregnancies; less interest in having children; less emphasis on romantic love; placed less importance on their social life; showed reduced family stability; were more extraverted; and were divorced or separated from their spouses more frequently.

Read more:
Genetic factors linked to gay men

14-06-2012 10:32 Dr. Riordan shows a video documenting the progress of a T-12 spinal cord injury patient after her combined bone marrow and umbilical cord stem cell treatment in Panama. He shows another video of a 65 year-old man (T-9) who was treated 13 years after his injury. This case illustrates the potential of treating older people whose injuries occurred many years prior to treatment. Treatment information at More information on Dr. Riordan at

Originally posted here:
Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 4 of 5) || Stem Cell Treatments - Video

Public release date: 15-Jun-2012 [ | E-mail | Share ]

Contact: Jeremy Moore Jeremy.Moore@aacr.org 215-446-7109 American Association for Cancer Research

PHILADELPHIA A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

"Very little was known about the genetic and molecular defects causing NK/T-cell lymphoma before we started this work," said Bin Tean Teh, M.D., Ph.D., director of the National Cancer Center Singapore-Van Andel Research Institute Translational Research Laboratory at the NCCS, and professor at the Duke-NUS Graduate Medical School in Singapore. "There is no effective treatment and this type of cancer carries an extremely poor prognosis.

"It is tremendously rewarding to have identified genetic mutations that appear to have an important role in driving the cancer in a considerable fraction of cases. Moreover, we are excited that there is a drug already in phase III trials for the treatment of rheumatoid arthritis that targets the mutant protein. We are in the process of planning a clinical trial to study whether this drug benefits NK/T-cell lymphoma patients," said Teh.

NK/T-cell lymphoma is a very aggressive form of lymphoma. It is particularly prevalent in Asia.

"Many years ago, I and a colleague came to the Van Andel Research Institute in Grand Rapids, Mich.," said Teh. "My colleague unfortunately developed NK/T-cell lymphoma and passed away. It was the only case of this cancer ever diagnosed in Grand Rapids. As this illustrates, it is a relatively rare subtype of lymphoma in the United States, but it is responsible for the deaths of a large number of people in Asia, in particular in China and Korea. It accounts for almost half of all T-cell lymphomas in some parts of Asia.

"The passing of my colleague, whom I was very close to, was the reason that I started studying NK/T-cell lymphoma. It has been a complicated puzzle, but I feel that we have pieced together enough that we will have an impact on a large number of patients with this disease."

To identify genetic mutations that might have a functional consequence, Teh and his colleagues sequenced all the genes in NK/T-cell lymphoma cells from four patients. In addition to mutations in genes known to be associated with cancer, they detected mutations in the Janus Kinase 3 (JAK3) gene in the cancer cells from half of the patients. The researchers conducted follow-up sequencing of NK/T-cell lymphoma cells from an additional 65 patients and identified JAK3 mutations in 23 of those patients.

The mutations enabled NK/T-cell lymphoma cell lines to grow in culture in the absence of the normally essential growth factor IL-2. This meant that the mutations caused dysregulated activation of JAK3, and suggested that JAK3 might be a good drug target.

Continued here:
Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target

by Cathy Marshall

kgw.com

Posted on June 15, 2012 at 6:01 AM

Updated today at 6:09 AM

With a blood sample from the mother and a swab of saliva from the father scientists could soon be able to screen unborn babies for more than 3,000 genetic disorders.

Currently the only routine test if for Downs Syndrome.

This might give peace of mind if they dont find problems. On the other hand what do you do about problems? Can you treat them? Will lit lead to more abortions? said CNN Medical Correspondent Dr. Bruce Hensel.

Scientists at the University of Washington were able to map the genetics of a fetus with 99 percent accuracy. The breakthrough can detect genetic mutations like if a child is predisposed to cancer.

If you think of a genome as a book and a healthy person has two copies of every chapter. We are trying to pick up the typos and single words on a single page, explained UW researcher Dr. Jay Shendure.

Some of the mutations are certain, telling if a child will be born with a disability. Others are less certain, indicating a baby has a greater likelihood of developing a disorder.

See the original post:
Unborn genetic tests being perfected at UW for 3K disorders

SAN MARINO, Calif.--(BUSINESS WIRE)--

VG Energy, the majority-owned subsidiary of Viral Genetics (Pink Sheets: VRAL), has entered into an agreement with UniQuest Pty. Ltd., the commercialization arm of the University of Queensland, Australia, tooptimize the use of Metabolic Disruption Technology (MDT) compounds in algae lipid production. Optimization will occur through experiments leading to the identification of the ideal concentration, timing and amount of MDT compounds to use. The multi-part study will begin with ten of the most commercially-viable algae strains in their optimized production environments, and narrow the set down to one, top-responding strain. The study is intended to guide the subsequent design of advanced commercialization and scale-up studies using the optimized strain, production method and dosing. VG Energy researchers have shown in multiple studies to produce a 10%-300% increase in the lipids produced by various strains of algae and other plant sources that can potentially be distilled into biofuel, and other high value oils for the food, cosmetics and nutraceuticals industries.

The project will be carried out by Associate Professor Ben Hankamer of the University of Queenslands Institute for Molecular Bioscience via its main commercialization company, UniQuest Pty. Ltd. (http://www.uniquest.com.au) and is expected to take several months. Ben Hankamer is the director of the Solar Biofuels Consortium, which brings together seven international teams and approximately 100 researchers (www.solarbiofuels.org) working on biofuels and production optimization. The consortium fosters close partnerships with industries that have synergy to establish effective value chains including the biotechnology, engineering, oil, airline and manufacturing industries.

Monica Ord, Viral Genetics Senior VP of Corporate Development commented, saying, We arethrilled to be working with UniQuest, Solar BiofuelsConsortium and Professor Ben Hankamer. Their production processes, scientists and technology are some of the highest quality available today. This opportunitygives us the capability toaccess input froma consortiumofresearchers and uniqueprocesses to bringourproduct to theoptimal level. We are very grateful to David White of Virgin Australia formaking theintroduction toProfessor Hankamerseven months ago.Since that time we have completedadditional internal studies andhave successfully finalized the protocols for this analysis, which will help move us along to the next step toward commercialization of the product. We are excited to get started.

About VG Energy

VG Energy, Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc., a biotechnology company researching new treatments and methods of detection for diseases including cancer, HIV/AIDS and others. Using its Metabolic Disruption Technology (MDT), Viral Genetics cancer research led to discoveries with major consequences in a wide variety of other industries, including biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. These pivotal discoveries promise to allow the biofuel industry to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit http://www.vgenergy.net.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit http://www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Read the original here:
VG Energy to Optimize Algae “Lipid Trigger” Compound with Leading Biofuel Researcher

SAN DIEGO, June 15, 2012 /PRNewswire/ --ViaCyte, Inc. today announced the appointment of seasoned entrepreneur, Paul Laikind, Ph.D., as President & Chief Executive Officer. Allan Robins, Ph.D., who was serving as Acting CEO, will continue in his role as Vice President & Chief Technology Officer. ViaCyte is a leading pre-clinical company developing a novel cell therapy product for the treatment of insulin dependent diabetes.

Dr. Laikind brings over 25 years of leadership experience in the biotechnology and life sciences industry to ViaCyte. He is a serial entrepreneur, who co-founded three San Diego companies, Gensia Pharmaceuticals Inc., Viagene Inc., and Metabasis Therapeutics Inc., serving in various executive positions including President and CEO. All three companies went public and were eventually acquired. Most recently, he served as Chief Business Officer and Senior Vice President of Business Development at the Sanford-Burnham Medical Research Institute.

"Paul brings to ViaCyte a wealth of experience in managing new businesses based on highly innovative life sciences technologies," said Fred Middleton, Chairman of ViaCyte. "We are pleased to have him join to lead ViaCyte through our next phase of development in bringing our transformative stem cell therapy to patients with diabetes. We believe Paul's leadership and business development skills will greatly assist us in our strategy to be a leader in regenerative medicine therapy and to capitalize on our current technology leadership position in the development of stem cell therapy."

As Sanford-Burnham's first Chief Business Officer, Dr. Laikind set a new direction for the Institute's business development activity through a combination of licensing and strategic partnerships with large pharmaceutical organizations, including collaborations with Pfizer's Centers for Therapeutic Innovation, Ortho-McNeil-Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, and Takeda Pharmaceutical. Working with the Institute's leadership team he helped establish a sophisticated infrastructure for advanced drug discovery and development at Sanford-Burnham.

Prior to Sanford-Burnham, Dr. Laikind served as President & CEO from 1999-2008 for Metabasis Therapeutics, which developed new therapies for metabolic and liver diseases. Dr. Laikind co-founded Gensia Pharmaceuticals in 1986, was a board member of the company and held various executive leadership positions. While at Gensia he was responsible for establishing a number of important strategic partnerships. In 1997, he was part of a team that restructured Gensia to focus on specialty pharmaceuticals. The restructured company was renamed Gensia Sicor and went on to be acquired for over $3 billion by Teva Pharmaceutical Industries in 2004. Soon after founding Gensia, he was co-founder of Viagene, a gene therapy company. Viagene completed an initial public offering in 1993 and was acquired in 1995 by Chiron Inc., now a subsidiary of Novartis Vaccines & Diagnostics.

Dr. Laikind earned his Ph.D. in biochemistry from the University of California, San Diego and is the inventor on a number of key patents.

"ViaCyte addresses one of the largest commercial and medical opportunities in stem-cell-derived therapeutics, and its team is internationally recognized for its scientific leadership," said Dr. Laikind. "I look forward to working with ViaCyte through clinical development and market launch of its first important product that promises to change the way we treat insulin dependent diabetes."

About ViaCyte

ViaCyte is a preclinical cell therapy company focused on diabetes. The Company's technology is based on pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine.

Read more:
ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer

Miami, FL (PRWEB) June 15, 2012

Cell therapy may be effective against arthritis of fingers, says A.J. Farshchian MD from the Center for regenerative medicine.

A very common type of arthritis that we encounter here is Osteoarthritis of fingers. This is even becoming more common no thanks to advancements in technology. (use of computer keyboard or videogames or certain pocket organizers and cell phones) Repetitive motion is most likely the number one cause of osteoarthritis of fingers, common sign of osteoarthritis in the fingers is a knobby bony deformity at the smallest joint of the end of the fingers. This is called Heberden's node. The bony deformity is a result of the bone spurs or osteophytes from the osteoarthritis in that joint. This deformity limits the range of motion of the joint. Typically is not painful but sometimes patient may experience severe pain in the fingers.

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme.

Continue reading here:
Cell Therapy is now being used for Arthritis of Fingers at the Center for Regenerative Medicine

DENVER--(BUSINESS WIRE)--

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference. The case reported was drawn from a Phase 1 study to assess the safety of this new investigational therapy for the leading cause of vision loss and blindness. Salutaris Medical Devices, Inc. (SalutarisMD) developed the device and sponsored the study.

Presented was the clinical course of a 78 year-old man newly diagnosed with Wet AMD who experienced substantial improvement in visual acuity and required no additional anti-VEGF injections throughout one-year follow-up; visual acuity in the study eye demonstrated a gain in Best Corrected Visual Acuity (BCVA) of +13 ETDRS letters, with no sign of subretinal hemorrhage, fluid or macular edema, and resolution of the Pigmented Epithelial Detachment (PED) present at study enrollment.

Co-author, Dr. Laurence Marsteller, Chief Operating Officer, SalutarisMD, cautioned, "While the results presented are not intended to be extrapolated for statistical significance, this promising case report from the Phase 1 trial supports the need for additional research to confirm our preliminary observations."

The poster presentation included details of the device and the sub-Tenon episcleral approach to delivering brachytherapy that avoids adverse effects of more invasive approaches. The SalutarisMD device is designed to enable retina specialists to administer a practical procedural therapy that can be performed in the same clinical environment as current anti-VEGF injections: a physician's office or other outpatient setting under local anesthesia, in approximately 15 minutes. The intraocular space is never violated. Episcleral placement allows for consistent, stable and repeatable control of the distance to the target tissue. Utilizing this minimally invasive technology, the retina specialist delivers precise, lesion-specific, localized tissue treatment.

"What is most intriguing about the study is that the application of radiation is done through the posterior sclera, thus avoiding the need for vitreous surgery," said Dr. Reid Schindler, principal investigator of the study, a clinical ophthalmologist and retina specialist with Retina Specialists of Southern Arizona, and clinical associate professor, University of Arizona Department of Ophthalmology.

Michael Voevodsky, President and CEO of SalutarisMD, said, "It was a privilege to have the SalutarisMD technology presented at this prestigious gathering. We believe our investigational therapy for treating Wet AMD has the potential to improve the quality of life for persons suffering from this debilitating disease. We are excited about the prospect of conducting additional clinical trials to further test our approach and its ability to positively effect clinical outcomes."

The purpose of the ARVO Conference,Drug and Gene Delivery to the Back of the Eye: from Bench to Bedside, "is to share cutting edge science, based on drug product development principles among a diverse group of participants" and it focuses "on topics related to current and emerging technologies for drug/gene delivery for the treatment of diseases of the back of the eye," according to the event description.

Caution: Investigational Device. Limited by Federal Law to Investigational Use in the United States.

About SalutarisMD

See original here:
SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO

14 June 2012 Last updated at 20:29 ET

Scientists say they have identified a possible genetic link between diabetes and Alzheimer's disease.

It has been known for some time that people with diabetes have a much higher risk of developing Alzheimer's, but not why this is so.

Now US researchers writing in Genetics say a study of worms has indicated a known Alzheimer's gene also plays a role in the way insulin is processed.

Dementia experts said more work in humans was now needed.

Alzheimer's is the most common cause of dementia, which affects 820,000 people in the UK.

There are medications which can slow the progress of the disease, but none that can halt its progress.

A key indication of Alzheimer's, which can only be seen after death, is the presence of sticky plaques of amyloid protein in decimated portions of patients' brains.

Scientists have already found mutations in a gene involved in the processing of amyloid protein in Alzheimer's which run in families.

In this study, a team from the City College of New York looked at a similar gene in the nematode worms (C. elegans).

Here is the original post:
Alzheimer's gene 'diabetes link'

CARLSBAD, Calif.--(BUSINESS WIRE)--

International Stem Cell Corporation (ISCO) http://www.internationalstemcell.com announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs." TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products.

In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells. In addition, the TTF proteins are naturally eliminated by the cells when no longer required, a characteristic that further improves safety. The Company intends that this technology, once perfected, will first be used to create revenue-generating research products for sale through Lifeline Cell Technologys international distribution channels to the academic, biotechnology and pharmaceutical markets for cellular proteins, including the quickly growing markets for the study of stem cell biology and drug testing.

According to Jeffrey Janus, Lifeline Cell Technologys CEO, These proteins can be sold into the market for cellular proteins which exceeds $700 million and represents an excellent opportunity for LCT to grow sales. Since the technology also has broad application in research and therapy, it should provide ISCO with future out-licensing opportunities to the biotechnology and pharmaceutical industries.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Read more:
International Stem Cell Corporation Scientists Create New Protein-Based Stem Cell Technology